Phase 2 Study of Rapcabtagene Autoleucel in Myositis
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
Active, not recruiting · NCT06665256 · Registry updated 2026-06-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase 2 Study of Rapcabtagene Autoleucel in Myositis | Skin and Connective Tissue Diseases, acquired idiopathic inflammatory myopathy, connective tissue disorder, dermatomyositis, interstitial lung disease, lung disorder, muscle tissue disorder, musculoskeletal system disorder, myositis disease, nervous system disorder, neuromuscular disease, polymyositis, respiratory system disorder, skin disorder | Active, not recruiting | Phase 2 | 2026-06-23 | NCT06665256 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Novartis Pharmaceuticals | 432 |
10 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Augusta University Georgia | Augusta | United States | 8 |
| Baylor University Medical Center | Dallas | United States | 87 |
| Duke Clinical Research Institute | Durham | United States | 3 |
| FL Medical Clinic Orlando Health | Zephyrhills | United States | 3 |
| Houston Methodist Hospital | Houston | United States | 260 |
| LDS Hospital | Salt Lake City | United States | 82 |
| Northwestern University | Chicago | United States | 727 |
| University of Alabama | Birmingham | United States | 29 |
| University of Iowa | Iowa City | United States | 284 |
| University of Pittsburgh Medical Center | Pittsburgh | United States | 10 |